Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 8/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 2/20 | 0.39 |
| ▸ | MC3R | P41968 | 2/20 | 0.39 |
| ▸ | MC1R | Q01726 | 2/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12482320 | 0.89 | SMN1; SMN2 (0.48) | TACR1ALDH1A1CYP2C19SMN1; SMN2HSD11B1 | |
| SCHEMBL6952343 | 0.86 | L3MBTL1 (0.49) | TACR1SMN1; SMN2HSD11B1MC4RMC3R | |
| SCHEMBL206989 | 0.85 | TACR1 (0.46) | TACR1CYP2C19HSD11B1MC4RMC3R | |
| SCHEMBL7854892 | 0.81 | TACR1 (0.63) | TACR1HSD11B1MC4RMC3RMC1R | |
| SCHEMBL18862951 | 0.80 | HSD11B1 (0.48) | HSD11B1MC4RMC3RMC1R | |
| SCHEMBL18862950 | 0.80 | HSD11B1 (0.48) | HSD11B1MC4RMC3RMC1R | |
| SCHEMBL29187960 | 0.79 | TACR1 (0.52) | TACR1HSD11B1MC4RMC3RMC1R | |
| SCHEMBL28169013 | 0.79 | TACR3 (0.50) | CYP2C19GAA | |
| SCHEMBL13722390 | 0.79 | TACR1 (0.46) | TACR1HSD11B1MC4RMC3RMC1R | |
| Hydrochloric Acid SCHEMBL5811944 | 0.79 | TACR1 (0.42) | TACR1HSD11B1SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2678336-B1 | THIAZOLYLPHENYL-BENZENESULFONAMIDO DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-04-20 | — | — | EP | disclosed |
| US-9199979-B2 | Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-12-01 | — | — | US | disclosed |
| EP-2678336-A1 | THIAZOLYLPHENYL-BENZENESULFONAMIDO DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2014-01-01 | — | — | EP | disclosed |
| US-20130324551-A1 | THIAZOLYLPHENYL-BENZENESULFONAMIDO DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-12-05 | — | — | US | disclosed |
| WO-2012113774-A1 | THIAZOLYLPHENYL-BENZENESULFONAMIDO DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324551-A1 | THIAZOLYLPHENYL-BENZENESULFONAMIDO DERIVATIVES AS KINASE INHIBITORS | MAP3K6, MAP3K1, MAP3K5 | TACR1 3190/4885ALDH1A1 2162/4885CYP2C19 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.